Axolotl Biologix

12 articles about Axolotl Biologix

• Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

  3/27/2024

  Carmell Corporation announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.

• Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine

  9/12/2023

  Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics.

• Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics

  9/5/2023

  Carmell Corporation, a regenerative care company, announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company.

• Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

  8/9/2023

  Carmell Corporation, a regenerative care company announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications.

• Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company

  7/27/2023

  Carmell Therapeutics Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative medicine company today announced the execution of a definitive agreement and plan of merger (the “Merger Agreement”) with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“Axolotl”).

• Centers for Medicare and Medicaid Services Makes It Easier for Healthcare Providers to Choose Axolotl Biologix Products to Spur Wound and Tissue Regeneration

  10/24/2019

  Axolotl’s DualGraft™ and Axolotl Graft™ products have been assigned the code Q4210.

• Axolotl Biologix Regenerative Medicine Product Line Approved For Veterans

  6/14/2019

  Axolotl Biologix, a biotechnology leader in regenerative medicine, is thrilled that the General Services Administration (GSA) has added the complete line of Axolotl Biologix’s products to the Federal Supply Schedule (FSS).

• Axolotl Biologix CSO Recognized Among Arizona’s Top Healthcare Leaders

  5/23/2019

  Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce its Chief Science Officer, Robert Kellar, Ph.D., has been recognized as one of Arizona’s top healthcare leaders.

• Axolotl Biologix Launches New Axolotl Shot™ For Wound Care

  12/15/2018

  Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl Shot™, an ambient temperature regenerative fluid preloaded into a syringe for ease of use by physicians.

• Axolotl Biologix Launches AxoBioFluid A An Ambient Temperature Amnion-Derived Allograft Fluid

  9/13/2017

• Axolotl Biologix To Attend The National Congress Of American Indians 73rd Annual Conference

  10/5/2016

• Axolotl Biologix To Attend The National Indian Health Board's 33rd Annual Consumer Conference And 2016 National Tribal Health Conference

  9/13/2016